Janux Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.61M, a 361.89% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.34M, a 91.86% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $227.00K, a 11.82% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$449.00K, a 411.81% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $827.00K, a 74.79% decline from fiscal 2024.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $3.28M.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$210.00K, a 106.23% decline from fiscal 2022.
- Janux Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.37M, a 86.65% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.96M 10-Q · filed 2026-08-06 | $3.18M derived: sum of 3 quarters · filed 2026-08-06 | $2.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.34M 10-Q · filed 2026-05-07 | $1.57M derived: sum of 2 quarters · filed 2026-05-07 | $1.12M derived: sum of 3 quarters · filed 2026-05-07 | $1.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$222.00K derived: sum of 2 quarters · filed 2026-02-26 | $127.00K derived: sum of 3 quarters · filed 2026-08-06 | $827.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$449.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$100.00K derived: sum of 2 quarters · filed 2026-08-06 | $600.00K 10-Q · filed 2025-11-06 | $803.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.05M 10-Q · filed 2026-08-06 | $1.25M derived: sum of 3 quarters · filed 2026-08-06 | $1.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $700.00K 10-Q · filed 2026-05-07 | $903.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.05M derived: sum of 3 quarters · filed 2026-05-07 | $2.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $347.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.11M derived: sum of 3 quarters · filed 2026-02-26 | $3.28M 10-K · filed 2026-02-26 |
| 2024-09-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.91M derived: sum of 2 quarters · filed 2025-11-06 | $3.08M 10-Q · filed 2025-11-06 | $2.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.93M 10-Q · filed 2025-08-07 | $2.66M derived: sum of 3 quarters · filed 2026-02-26 | $2.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-08 | $901.00K derived: sum of 2 quarters · filed 2026-02-26 | $371.00K derived: sum of 3 quarters · filed 2026-02-26 | $2.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$800.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.44M derived: sum of 3 quarters · filed 2026-02-26 | -$210.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$530.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.71M derived: sum of 2 quarters · filed 2024-11-06 | $60.00K 10-Q · filed 2024-11-06 | $141.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $590.00K 10-Q · filed 2024-08-07 | $671.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.65M 10-Q · filed 2024-05-08 | -$1.57M derived: sum of 2 quarters · filed 2025-02-27 | -$267.00K derived: sum of 3 quarters · filed 2025-02-27 | $320.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.38M derived: sum of 2 quarters · filed 2025-02-27 | $1.97M derived: sum of 3 quarters · filed 2025-02-27 | $3.37M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.89M derived: sum of 2 quarters · filed 2023-11-07 | $3.29M 10-Q · filed 2023-11-07 | $3.26M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $587.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.99M 10-Q · filed 2023-08-08 | $1.96M derived: sum of 3 quarters · filed 2023-08-08 | $2.00M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-09 | $1.37M derived: sum of 2 quarters · filed 2023-05-09 | $1.42M derived: sum of 3 quarters · filed 2023-05-09 | $3.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $16.00K derived: sum of 2 quarters · filed 2023-03-10 | $1.79M derived: sum of 3 quarters · filed 2023-03-10 | $1.80M 10-K · filed 2023-03-10 |
| 2021-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.82M derived: sum of 2 quarters · filed 2022-11-10 | $1.83M 10-Q · filed 2022-11-10 | $2.08M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.79M 10-Q · filed 2022-08-09 | $2.04M derived: sum of 3 quarters · filed 2022-08-09 | $2.04M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $13.00K 10-Q · filed 2022-05-10 | $262.00K derived: sum of 2 quarters · filed 2022-05-10 | $262.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $249.00K derived: sum of 2 quarters · filed 2022-03-18 | $249.00K 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |